2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma.

Autor:	Cerci JJ; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Linardi CC; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Pracchia LF; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Junior JS; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Trindade E; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Delbeke D; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Cerci RJ; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Carr R; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Meneghetti JC; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil., Buccheri V; Juliano J Cerci, José Soares Junior, José C Meneghetti, Department of Nuclear Medicine, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-900, Brazil.
Jazyk:	angličtina
Zdroj:	World journal of radiology [World J Radiol] 2013 Dec 28; Vol. 5 (12), pp. 484-90.
DOI:	10.4329/wjr.v5.i12.484
Abstrakt:	Aim: To assess the prognostic value and risk classification improvement of metabolic staging (MS) with Initial 2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography (FDG-PET) in initial staging of Hodgkin's Lymphoma (HL) patients to predict 5 years overall survival (5y-OS) and event free survival (EFS). Methods: A total of 275 patients were included in this retrospective study, 155 patients were staged with conventional anatomical staging (AS), and 120 also submitted to MS (FDG-PET). Prognostic analysis compared 5y-OS and 5y-EFS of patients staged with AS and MS. Risk-adjusted models incorporated clinical risk factors, computed tomography and FDG-PET staging. Results: During the follow up of 267 evaluated patients, 220 (122 AS and 98 MS) achieved complete remission after first-line therapy (median follow-up: 70 ± 29 mo), treatment failure occurred in 79 patients and 34 died. The 5y-EFS for early vs advanced disease in AS patients was 79.3% and 66.7%, and 85.6% and 53.6% in MS patients, respectively (P < 0.01). The 5y-OS for early and advanced disease with AS was 91.3% and 81.5%, and 97.5% and 80.7% for patients staged with MS, respectively. Cox proportional hazards analysis demonstrated that FDG-PET added signiﬁcant prognostic information and improved risk prediction (P = 0.02). Conclusion: Initial staging FDG-PET could be used as an accurate and independent predictor of OS and EFS in HL, with impact in 5y-EFS and OS.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu